Avrobio (Avrobio) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Avrobio 3-Year Dividend Growth Rate?

Avrobio's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The historical rank and industry rank for Avrobio's 3-Year Dividend Growth Rate or its related term are showing as below:

AVRO's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.8
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Avrobio's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Avrobio's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Avrobio's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Avrobio's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avrobio's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avrobio's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Avrobio's 3-Year Dividend Growth Rate falls into.

Avrobio 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Avrobio (NAS:AVRO) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Avrobio's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.15
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avrobio 3-Year Dividend Growth Rate Related Terms>

Avrobio (Avrobio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avrobio Inc (NAS:AVRO) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, Sixth Floor, Cambridge, MA, USA, 02139

Website

https://www.avrobio.com

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.

Executives

Azadeh Golipour	officer: Chief Technology Officer	ONE KENDALL SQUARE, BLD. 300 - SUITE 201, CAMBRIDGE MA 02139
Essra Ridha	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQUARE, BLDG 300 - SUITE 201, CAMBRIDGE MA 02139
Philip J. Vickers	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Christopher Mason	officer: Chief Scientific Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Phillip B. Donenberg	director	C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 200, BANNOCKBURN IL 60015
Diana Escolar	officer: Chief Medical Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Gail M Farfel	director	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Deanna M Petersen	officer: Chief Business Officer	45 FIRST AVENUE, WALTHAM MA 02451
Geoffrey Mackay	director, officer: See Remarks	C/O AVROBIO, INC., ONE KENDALL SQ, BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Christopher Paige	director	C/O AVROBIO INC, ONE KENDALL SQ, BLDG 300, STE 201, CAMBRIDGE MA 02139
Atlas Venture Fund X, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, Llc	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund I, L.p.	other: See Remarks	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451